Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma

Wu, S; Blombery, P; Westerman, D; Tam, CS

Author(s): Wu, S; Blombery, P; Westerman, D; Tam, CS;
Details: Publication Year 2023-08,Volume 24,Issue #8,Page 929-947
Journal Title: Current Treatment Options in Oncology
Publication Type: Review
Abstract: Mantle cell lymphoma (MCL) treatment advances have significantly improved disease-free remission, with greater focus in clinical trials being placed on measurable residual disease (MRD) as a marker of subclinical disease assessment. While this concept is used extensively in other haematological neoplasms, there is yet to be a consensus on the threshold for MRD in MCL that demonstrates prognostic and therapeutic significance, and in this context has yet to reach routine clinical practice. The historical long-term method for MCL MRD assessment has been real-time quantitative polymerase chain reaction (PCR), targeting the clonal immunoglobulin heavy locus (IGH) rearrangement or the IGH::CCND1 translocation rearrangement. A significant problem at present relates to identifying alternative assays for patients who do not have a suitable molecular target by this method. This article reviews existing techniques used in MRD assessment for MCL and describes novel methods which may overcome existing limitations, including next-generation sequencing modalities. The use of circulating tumour DNA is explored, with techniques such as CAPP-Seq and PhasED-Seq demonstrating promise in B-lymphoproliferative disorders, though application in MCL requires further study. The other aspect of practice using MRD is identifying therapeutic options which can address a subclinical molecular relapse. Developing suitable interventions that can alter the disease trajectory based on longitudinal MRD kinetics are needed to justify its incorporation into standard care.
Publisher: Springer Nature
Keywords: Adult; Humans; *Lymphoma, Mantle-Cell/diagnosis/genetics/therapy; Neoplasm Recurrence, Local/genetics; Translocation, Genetic; Prognosis; Neoplasm, Residual/diagnosis/genetics; Circulating tumour DNA; Mantle cell lymphoma; Measurable residual disease; Minimal residual disease; Next-generation sequencing
Department(s): Clinical Haematology; Pathology
PubMed ID: 37249800
Publisher's Version: https://doi.org/10.1007/s11864-023-01102-2
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-10-16 11:42:28

Last Modified: 2024-07-30 01:55:44